

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DODD, G.

Atty. Ref.: 2491-47

Serial No. 10/505,429

Group: Unassigned

Filed: August 24, 2004

Examiner: Unassigned

For: TREATMENT OF FEMALE SEXUAL DYSFUNCTION

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 10, 2004

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2491-47

10/505,429

APPLICANT

DODD, G.

(Use several sheets if necessary)

FILING DATE

GROUP

August 24, 2004

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	<b>Ohloff et al</b> , Chemical Classification & Structure – Odour relationships, in perfumes: Art, Science & Technology, Elsevier 1991, pp 287-330
	<b>Menco et al</b> , Presence of Membrane Particles in Freeze-Etched Bovine Olfactory Cilia, Nature, October 14, 1976, Vol. 263, pp 597-599
	<b>Menevse et al</b> , Biochemical and Biophysical Research Communications, 1977, Vol. 77, No. 2, pp 671-677
	<b>Shirley et al</b> , Biochem. J., 1987, Vol. 245, pp 175-184
	<b>Kirk-Smith et al</b> , Biological Psychology, 1983, Vol. 17, pp 221-231
	<b>Van Toller et al</b> , Biological Psychology, 1983, Vol. 16, pp 85-107
	<b>Van Toller et al</b> , Ageing and the Sense of Smell, Charles C. Thomas Publisher, 1985
	<b>Dodd et al</b> , The Biochemistry and Psychology of Perfumery, August/September 1983, Vol. 8, pp 1-14
	<b>Van Toller et al</b> , Perfumery: The Psychology and Biology of Fragrance, Chapman and Hall Ltd, 1988
	<b>Van Toller et al</b> , Fragrance: The Psychology and Biology of Perfume, 1992
	<b>Calkin et al</b> , Perfumery: Practice and Principles, Wiley-Interscience Publication, 1994
	<b>Ancill et al</b> , Schizophrenia: Exploring the Spectrum of Psychosis, John Wiley & Sons, 1994
	<b>Bancroft et al</b> , Human Sexuality and Its Problems, Churchill Livingstone, 1989
	<b>Cohn et al</b> , Biochemistry and Disease: Bridging Basic Science and Clinical Practice, Williams & Wilkins, 1996
	<b>Hollandsworth et al</b> , The Physiology of Psychological Disorders, Plenum Press, 1990
	<b>Muller et al</b> , Perfumes: Art, Science and Technology, Elsevier Applied Science, 1990
	<b>Paykel</b> , Handbook of Affective Disorders, The Guilford Press, 1982
	<b>Smith</b> , Elements of Molecular Neurobiology, John Wiley & Sons, 1996
	<b>Snyder</b> , Drugs and the Brain, 1986
	<b>Stahl</b> , Essential Psychopharmacology, Cambridge University Press, 1996

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2491-47

10/505,429

APPLICANT

DODD, G.

(Use several sheets if necessary)

FILING DATE

GROUP

August 24, 2004

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	<b>Strong et al</b> , Human Sexuality, Mayfield Publishing Company, Fourth Edition, 1994
	<b>Wingard et al</b> , Human Pharmacology: Molecular to Clinical, Mosby Year Book, 1991
	<b>Crenshaw et al</b> , Journal of Sex & Marital Therapy, 1987, Vol. 13, No. 4, pp 239-252
	<b>Davis</b> , Journal of Sex & Marital Therapy, 1998, Vol. 24, pp 153-163
	<b>Dunn et al</b> , Family Practice, 1998, Vol. 15, No. 6, pp 519-524
	<b>Harvey</b> , British Journal of Psychiatry, 1988, Vo. 153, pp 833-836
	<b>Hyypa et al</b> , The Activating Effect of L-dopa Treatment on Sexual Functions and Its Experimental Background. Acta Neurologica Scand. 1970, 43 Supply 3: 223-234
	<b>Laumann et al</b> , JAMA, February 10, 1999, Vol. 281, No. 6, pp 537-544
	<b>O'Brien et al</b> , Arch Gen Psychiat, January 1971, Vol. 24, pp 61-64
	<b>Pfaus</b> , The Pharmacology of Sexual Function and Dysfunction, Amsterdam, Elsevier Science BV, 1995, pp 37-48
	<b>Riley et al</b> , Sexual Desire Disorders, In GO Gabbard (Ed). Treatment of Psychiatric Disorders. Third Edition. Washington, American Psychiatric Publishing mc, 2001, pp 1849-1871
	<b>Riley et al</b> , Journal of Sex & Marital Therapy, 2000, Vol. 26, pp 269-283
	<b>Segraves et al</b> , Journal of Sex & Marital Therapy, 2001, Vol. 27, pp 303-316
	<b>Nadelson et al</b> , Treatment Interventions in Human Sexuality (New York: Plenum Press, 1983)

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)